Dicerna Pharmaceuticals Inc
DelistedCIK 1399529fmd_1EEM50ZH85XEVM1HST6GKJ43WBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2021, 36 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 7 | 0 | 0 | 0 | 0 | 1 | 6 | 24 | 164 |
| Research and development | 12 | 12 | 29 | 44 | 41 | 36 | 46 | 109 | 205 |
| Total operating expenses | 16 | 17 | 45 | 63 | 60 | 62 | 97 | 152 | 278 |
| Operating income | – | (17) | (45) | (63) | (60) | (61) | (90) | (128) | (113) |
| Interest expense | 1 | 1 | 0 | – | 0 | 0 | 1 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 8 | 6 |
| Other non-operating income (expense) | (1) | (1) | (3) | 0 | 0 | 1 | 1 | 8 | 0 |
| Net income from continuing operations | (9) | (17) | (45) | – | – | – | – | – | – |
| Net income | (10) | (19) | (48) | (63) | (60) | (60) | (89) | (120) | (113) |
| Net income to common shareholders | (14) | (21) | (48) | (63) | (60) | (80) | (89) | (120) | – |